New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9200-0.0100 (-0.52%)
At close: 01:00PM EST
1.9000 -0.02 (-1.04%)
After hours: 03:54PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 99.93M
Enterprise value 56.38M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.66
Price/book (mrq)3.08
Enterprise value/revenue 3.19
Enterprise value/EBITDA -0.58

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-86.68%
S&P500 52-week change 3-13.51%
52-week high 316.3000
52-week low 30.6800
50-day moving average 31.8721
200-day moving average 33.1510

Share statistics

Avg vol (3-month) 38.18M
Avg vol (10-day) 3691.7k
Shares outstanding 551.78M
Implied shares outstanding 6N/A
Float 837.58M
% held by insiders 123.35%
% held by institutions 138.72%
Shares short (30 Oct 2022) 41.23M
Short ratio (30 Oct 2022) 40.64
Short % of float (30 Oct 2022) 44.12%
Short % of shares outstanding (30 Oct 2022) 43.50%
Shares short (prior month 29 Sept 2022) 42.16M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-952.41%

Management effectiveness

Return on assets (ttm)-50.15%
Return on equity (ttm)-141.88%

Income statement

Revenue (ttm)8.81M
Revenue per share (ttm)0.26
Quarterly revenue growth (yoy)-34.50%
Gross profit (ttm)-42.11M
Net income avi to common (ttm)-102.43M
Diluted EPS (ttm)-3.2550
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.45M
Total cash per share (mrq)0.97
Total debt (mrq)6.9M
Total debt/equity (mrq)21.24
Current ratio (mrq)3.26
Book value per share (mrq)0.76

Cash flow statement

Operating cash flow (ttm)-79.56M
Levered free cash flow (ttm)-40.57M